학술논문
Continued Slow Decay of the Residual Plasma Viremia Level in HIV-1–Infected Adults Receiving Long-term Antiretroviral Therapy
Document Type
article
Author
Riddler, Sharon A; Aga, Evgenia; Bosch, Ronald J; Bastow, Barbara; Bedison, Margaret; Vagratian, David; Vaida, Florin; Eron, Joseph J; Gandhi, Rajesh T; Mellors, John W; Team, for the ACTG A5276s Protocol; Mirand, Amy; Klebert, Michael; Fry, Carrie; Dragavon, Joan; Koletar, Susan; Hite, Mark; Meixner, Linda; Seefried, Edward; Bagur, Jorge L Santana; Perez, Sigrid; Funk, Connie; Santos, Bartolo; Bailey, Vicki; Jackson, Brenda; Feinberg, Judith; Saemann, Michelle; Lindsey, Elizabeth; James, Tamara; Kronk, Catherine; Oakes, Jonathan; Adams, Mary; Hurley, Christine; Dunaway, Shelia; Storey, Sheryl S; Van Dam, Cornelius; Epperson, Kim; Tebas, Pablo; Thomas, Aleshia; Klevens, Lisa; Mattiucci, Sara; Walton, Trisha; Baum, Jane; Spitz, Teresa; DeMarco, Debra; Sha, Beverly E; Green, Tondria; Basler, Cathi; Griesmer, Christine; Aberg, Judith A; Cespedes, Michelle S; Valle, Sandra; Slamowitz, Debbie; Currier, Judith; Cajahuaringa, Vanessa; Taiwo, Babafemi; McGregor, Donna; Kumar, Princy; Timpone, Joseph; Albrecht, Mary; Kershaw, Andrea; Sax, Paul; Keenan, Cheryl; Daar, Eric; Lopez, Ruben; Luetkemeyer, Annie; Dwyer, Jay; Ellner, Jerrold; Linas, Benjamin; Hughes, Valery; Lopez-Detres, Luis; Davis, Traci; Whitely, Kim; Palmore, Melody; Gunthel, Clifford
Source
The Journal of Infectious Diseases. 213(4)
Subject
Language
Abstract
UnlabelledWe measured plasma human immunodeficiency virus type 1 (HIV-1) RNA levels by means of single-copy assay in 334 participants receiving virologically suppressive antiretroviral therapy (ART). A residual viremia load of ≥1 copy/mL after 4 years of ART was predicted by a higher pre-ART HIV-1 RNA level, higher CD8(+) T-cell count during treatment, and a lower ratio of CD4+ T cells to CD8+ T cells during treatment but not by initial ART regimen. In a longitudinal subset of 64 individuals, continued decay of the plasma HIV-1 RNA level was observed, with an average annual decrease of 6% and an estimated half-life of 11.5 years. In contrast to prior reports, the persistent viremia level continues to slowly decline during years 4-12 of suppressive ART.Clinical trials registrationNCT00001137.